Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

PALO ALTO, Calif.–(BUSINESS WIRE)–Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai’s platform maintained high sensitivity and specificity in both independent training and…